Medigene Refills Its Early Pipeline By Buying Trianta Immunotherapies
This article was originally published in The Pink Sheet Daily
For just under €10 million, Germany’s Medigene completes its restructuring with immunotherapy platform technologies that include dendritic cell vaccines, T-cell receptor based products and anti-T-cell monoclonal antibodies.
You may also be interested in...
Option lets the firm sell up to 25M Euros in new stock to YA Global over three-year period.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.